Management of Pregnant Women with Atrial Septal Defect and Pulmonary Hypertension: A Case Report
DOI:
https://doi.org/10.21776/ub/hsj.2024.005.02.13Keywords:
Congenital Heart Disease, Pulmonary Hypertension, Phospodiesterase-5 (PDE-5)-Inhibitor, Prostacyclin AnalogueAbstract
Backgrounds:
Pulmonary Hypertension (PH) is a condition where there is an increase in Pulmonary Vascular Resistance (PVR) and an increase in the mean Pulmonary Arterial Pressure (mPAP) to more than 20 mmHg. PH can occur in someone with Congenital Heart Disease (CHD). PH conditions can aggravate pregnancy in women with CHD. So that women with PH are recommended not to undergo pregnancy. However, it is possible for women with CHD with PH conditions to undergo pregnancy. In these conditions, optimizing PH therapy is important so that pregnant women with PH do not experience a worsening of the condition and can carry out their pregnancy well until delivery.
Â
Case Presentations:
A 38-year-old female patient with a history of Atrial Septal Defect-Pulmonary Hypertension came for routine control to the cardiac clinic with the condition of pregnancy of her 4th child who was just discovered when she was 6 months pregnant. Since giving birth to her third child, the patient began to complain of being easily tired when doing activities accompanied by swollen legs that disappeared with rest. At that time, the patient went to a cardiologist for an echocardiography examination and was diagnosed as Atrial Septal Defect (ASD)-Pulmonary Hypertension (PH). Since then, the patient has been routinely treated at a cardiologist with Pulmonary Hypertension drugs, including Phospodiesterase5 (PDE5) inhibitors (Sildenafil) and Prostacyclin Analogue (Dorner). The patient had done Transesophageal Echocardiography (TEE) with the results of ASD secundum suitable for closure by device. Patients with Right Heart Catheterization (RHC) results, ASD secundum with PH High Flow High Resistance reactive to Vasoreactivity Test. Since the patient was found to be pregnant, the patient continued to use Sildenafil and discontinued the use of Dorner. The patient then continued treatment in a multidisciplinary team.
Â
Conclusion :
Management of pregnant women with CHD and PH is important because the condition of PH itself further aggravates the condition of pregnancy. Medical management for PH in pregnant women follows the guidelines for the safety of drugs in pregnancy. So that the choice of therapy is crucial related to the goal of treatment to control the PH condition in the patient but still pay attention to safety in pregnancy conditions.
References
Martin SR, Edwards A. Pulmonary Hypertension and Pregnancy. Obstetrics and Gynecology 2019;134(5):974–87. 10.1097/AOG.0000000000003549
E.A. Orchard, N. Wilson, O.J.M. Ormerod. Device closure of atrial septal defect during pregnancy for recurrent cerebrovascular accidents. INTERNATIONAL JOURNAL OF CARDIOLOGY 2009;241–2.
Stokes MB, Xu B, Nerlekar N, Lockwood SM, Harper RW. Successful percutaneous closure of an extremely large secundum atrial septal defect during pregnancy. Cardiovasc Diagn Ther 2017;7(3):336–9. 10.21037/cdt.2016.10.03
Pieper PG, Hoendermis ES. Pregnancy in women with pulmonary hypertension. Netherlands Heart Journal 2011;19(12):504–8. 10.1007/s12471-011-0219-9
Sakurako Mishima, Takashi Mitsui, Satoshi Akagi, Tomohiro Mitoma. Pregnant Woman With Severe Pulmonary Hypertension Due to an Atrial Septal Defect That Was Triggered by Pregnancy. Res Sq 2022; https://doi.org/10.21203/rs.3.rs-1206711/v1
Luthra A, Bajaj R, Jafra A, Jangra K, Arya VK. Anesthesia in pregnancy with heart disease. Saudi J Anaesth. 2017;11(4):454–71. 10.4103/sja.SJA_277_17
Fernandes SM, Arendt KW, Landzberg MJ, Economy KE, Khairy P. Pregnant women with congenital heart disease: Cardiac, anesthetic and obstetrical implications. Expert Rev Cardiovasc Ther. 2010;8(3):439–48. 10.1586/erc.09.179
Huang S, DeSantis ERH. Treatment of pulmonary arterial hypertension in pregnancy. American Journal of Health-System Pharmacy. 2007;64(18):1922–6. 10.2146/ajhp060391
RA Curry, C Fletcher, E Gelson, MA Gatzoulis, M Woolnough. Pulmonary hypertension and pregnancy—a review of 12 pregnancies in nine women. An International Journal of Obstetric and Gynaecology 2012;
Afify H, Kong A, Bernal J, Elgendy IY. Pulmonary Hypertension in Pregnancy: Challenges and Solutions. Integr Blood Press Control. 2022;15:33–41. 10.2147/IBPC.S242242
Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in Pregnancy: A Systematic Review of Maternal Tolerance and Obstetric and Perinatal Outcomes. Fetal Diagn Ther. 2017;41(2):81–8. 10.1159/000453062
Madden BP. Pulmonary hypertension and pregnancy. Int J Obstet Anesth. 2009;18(2):156–64. 10.1016/j.ijoa.2008.10.006
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).